Remove Access Remove Cannabis Remove Extraction Remove Pharmaceutical
article thumbnail

The Pharmaceutical Industry’s Relationship With Cannabis

Kind Meds (Cannabis Education Blog)

Cannabis has had a long, changing history in the United States. Now, as the future of cannabis seems to be promising across the country, there are still many obstacles in the way of medical cannabis becoming legal. At the same time, the pharmaceutical industry has become one of the most powerful businesses in the country.

article thumbnail

Valcon Medical A/S Announces Receipt of EU GMP Certification and Start of Commercial Production for Pharmaceutical-Grade Cannabis Concentrates, Intermediary Products, and Medical Formulations

Cannabis Law Report

COPENHAGEN , June 22, 2021 /PRNewswire/ — Valcon Medical A/S (“Valcon Medical” or the “Company”), Denmark’s leading independent cannabis concentrate and medical formulation provider, received its licensing for the commercial production of cannabis from the Danish Medicines Agency (DKMA) earlier in May 2021.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Virginians No Longer Need a Medical Cannabis Card to Access their Stash

Veriheal

This month, patients will no longer require a medical cannabis card to participate in Virginia’s medical cannabis program. Patients no longer need to register through the Board of Pharmacy in order to legally buy medical cannabis in Virginia. Virginia’s Medical Cannabis Dispensaries Welcome Surge of New Customers .

Access 104
article thumbnail

Clever Leaves Holdings Begins Sales of Cannabis Extracts in Germany Through Ethypharm Partnership

Cannabis Law Report

We are one of the first to successfully complete a commercial shipment of Colombian-manufactured high-CBD pharmaceutical product to Germany available for patients in pharmacies under prescription. In addition, this reflects our increasing know-how to comply with complex and sophisticated regulatory and quality frameworks.

article thumbnail

Curaleaf International Advances Accessibility of Medical Cannabis Products in Germany with Strategic Partnership

Cannabis Law Report

Pharmaceutical and Medical Cannabis Leaders Zambon GmbH and Adven GmbH will Drive Medical Cannabis Supporting Treatments for Neurological Therapies. The aim of the agreement is to make medical cannabis treatments available to patients, with an initial focus on neurological therapies. It is expected to be worth USD 2.1

Access 105
article thumbnail

Dr. Andrew Weil on Cannabis and Integrative Medicine

Project CBD

NM: As someone who has been researching cannabis for decades, how do you feel about the current legalization situation worldwide and in Japan, in particular? Dr. Andrew Weil: I think the trend very clearly is that in most developed countries, cannabis is being made legal first for medical uses and then also for recreational uses.

Medicine 301
article thumbnail

Canopy Growth Divests Pharmaceutical C3 Cannabinoid Compound Company

Cannabis Law Report

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (NASDAQ: CGC ) has entered into an agreement to divest its subsidiary business, C³ Cannabinoid Compound Company GmbH (“C3”), to Dermapharm Holding SE (“Dermapharm”) (WKN: A2GS5D, ISIN: DE000A2GS5D8), a European pharmaceutical company headquartered in Grünwald, Germany.